Tyrosine News and Research

RSS

‘Dismal prognosis’ of blast-phase CML patients highlighted

A team of Mexican researchers reports on the poor outcomes of a large series of Mexican patients with chronic myeloid leukaemia in blast phase.

22 Oct 2015

Controlling TH-containing neurons can manipulate maternal behavior of females and aggression of males

Most female mammals give birth and care for their offspring, while the males often breed with multiple partners and play little role in parenting once the mating is over. Yet researchers have had a hard time pinpointing where, exactly, in the brain these differences between the sexes are located and how they translate into behavior. The extent of "hardwired parental behavior" is hotly disputed.

8 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

Chromosome 3q26.2 rearrangements linked to poor CML prognosis

Rearrangements of chromosome 3q26.2 have a significant negative impact on patients with chronic myeloid leukaemia, suggests research published in Blood.

1 Oct 2015

Beta-catenin shows treatment target potential for TKI-resistant CML

Nuclear β-catenin could be a treatment target for patients whose chronic myeloid leukaemia is resistant to tyrosine kinase inhibitors independent of additional BCR–BL1 mutations, US researchers suggest.

1 Oct 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour tissue as a sample. The test identifies 42 mutations in the epidermal growth factor receptor (EGFR) gene, the most of any In-vitro Diagnostic (IVD) on the market, and can also be used as an aid in selecting eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).

From Roche Sequencing and Life Science 28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

Researchers identify triple mechanism that prevents onset of chromosomal instability

Universitat Autònoma de Barcelona researchers have identified for the first time the triple mechanism that stops chromosome separation in response to situations that compromise the integrity of the genetic information. The loss of this response capacity is characteristic of cancerous cells.

18 Sep 2015

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

In metastatic renal cell carcinoma patients, there is no significant correlation between adverse event profiles of first- and second-line tyrosine kinase inhibitors, suggests a Japanese study.

17 Sep 2015

New findings on amitriptyline drug could help develop antidepressants with novel mechanisms

Researchers in Japan have shown that several different classes of antidepressants increase early growth responses in astrocytes, star-shaped glial cells, which could help develop new treatments.

16 Sep 2015

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces the completion of enrolment in a global Phase III clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

15 Sep 2015

New technique could improve selectivity of cancer drugs, decrease unwanted side effects in future

A class of therapeutic drugs known as protein kinase inhibitors has in the past decade become a powerful weapon in the fight against various life-threatening diseases, including certain types of leukemia, lung cancer, kidney cancer and squamous cell cancer of the head and neck.

11 Sep 2015

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015.

11 Sep 2015

Inhibition of Tyk2 enzyme promotes anti-cancer activity

Tyrosine kinase 2 (Tyk2) is an enzyme involved in intracellular signalling and has an important role in activating the immune system.

11 Sep 2015

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Two members of the vascular endothelial growth factor family are highly specific and moderately sensitive for the presence of pulmonary hypertension, report researchers.

10 Sep 2015

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).

8 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

Tyrosine News and Research

‘Dismal prognosis’ of blast-phase CML patients highlighted

Controlling TH-containing neurons can manipulate maternal behavior of females and aggression of males

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Chromosome 3q26.2 rearrangements linked to poor CML prognosis

Beta-catenin shows treatment target potential for TKI-resistant CML

New drug works better than current treatments for advanced kidney cancer

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

BGB324 shows enhanced tumour clearance in mouse carcinoma models

Researchers identify triple mechanism that prevents onset of chromosomal instability

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

New findings on amitriptyline drug could help develop antidepressants with novel mechanisms

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

New technique could improve selectivity of cancer drugs, decrease unwanted side effects in future

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Inhibition of Tyk2 enzyme promotes anti-cancer activity

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

AstraZeneca presents lung cancer research data at WCLC 2015

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News